Form 4: CRISPR Therapeutics Executive Sells Shares

Sentiment:

Insider Transaction (Form 4)


James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, sold 1,990 shares of common stock on October 6, 2026 for $60.04 per share.

Summary

  • Option exercise/conversion: acquired 1,990 Common Shares at $13.62 ($27,104) on October 6, 2026; holds 96,774 after (Direct).
  • Open-market sale: disposed of 1,990 Common Shares at $60.04 ($119,481) on October 6, 2026; holds 94,784 after (Direct).
  • Option exercise/conversion: disposed of 1,990 Stock Option (Right to Buy) on October 6, 2026; holds 81,242 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $119,481 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

James R. Kasinger — Officer (General Counsel and Secretary)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-10-06Option exercise/conversionCommon Shares1,990$14$27.1K96,774
2026-10-06Open-market saleCommon Shares1,990$60$119.5K94,784
2026-10-06Option exercise/conversionStock Option (Right to Buy)1,990——81,242

Key Dates

DateDescription
2026-10-06Option exercise/conversion (1,990 shares)
2026-10-06Open-market sale (1,990 shares)
2026-10-06Option exercise/conversion (1,990 shares)

Keywords

insider transaction, Form 4, CRSP, CRISPR Therapeutics AG, bearish, James R. Kasinger

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.